Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Recurrent cystitis
- Recurrent UTI (cystitis): risk factors
- Prevention of recurrent UTIs
- Predicting nomogram for recurrences
- Factors affecting recurrence-free in 768 patients
- Nomogram for risk prediction of recurrent UTIs (LUTIRE)
- Cystitis is detrimental for quality of life
- Preventative measures for recurrent cystitis
- Antimicrobial prophylaxis of recurrent cystitis
- Antimicrobial prophylaxis of recurrent UTI
- Contraindication of nitrofurantoin for prophylactic use in France
- Effective alternative preventative strategies must be envisaged
- Relative risk of symptomatic UTI
- Effect of increased daily water intake
- Effect of increased daily water intake: results
- Vaginal estrogen in postmenopausal women
- Probiotics
- Lactobacillus crispatus CTV-05 colonization pattern
- Cranberry products
- Anti-adhesion activity in urine of PAC
- Adhesion blockers: D-mannose
- Uro-Vaxom®-OM-89
- Uro-Vaxom® enhances the defenses against recurrent UTI
- Effectiveness of OM-89 on recurrent UTI in clinical studies (1)
- Effectiveness of OM-89 on recurrent UTI in clinical studies (2)
- Effectiveness of OM-89 on recurrent UTI in clinical studies: antibiotic consumption
- Effectiveness of OM-89 on recurrent UTI in clinical studies: QoL
- Effectiveness of OM-89 on rUTI in clinical studies: versus vaccines
- Safety profile of OM-89
- Beerepoot meta-analysis results
- Sublingual MV140 for prevention of recurrent UTIs (1)
- Sublingual MV140 for prevention of recurrent UTIs (2)
- Sublingual MV140: UTI episodes and recurrence
- Conclusions
- Thank you
Topics Covered
- Prevention of recurrent UTI (cystitis)
- Factors affecting recurrence
- Cystitis and quality of life
- Preventative measures for recurrent cystitis
- Antimicrobial prophylaxis of recurrent UTI
- Effect of increased daily water intake
- Probiotics containing specific strains might prevent recurrent UTI
- Cranberry products
- Uro-Vaxom® enhances the defenses against recurrent UTI
- Sublingual MV140 for prevention of recurrent UTIs
Talk Citation
Naber, K.G. (2023, November 30). Novel treatment and prophylaxis of uncomplicated urinary tract infections 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 12, 2024, from https://doi.org/10.69645/LNHA7069.Export Citation (RIS)
Publication History
Financial Disclosures
- Adamed Pharma: Consultant; Bionorica: Consultant, Scientific Presentations and Publications; Bio Merieux: Scientific Presentations; GlaxoSmithKline: Consultant; Ingenion Medical: Consultation; Janssen Pharmaceutica: Consultant; OM Pharma: Consultant, Scientific Presentations and Publications; MIP/Rosen Pharma: Consultant, Scientific Presentations and Publications.
Novel treatment and prophylaxis of uncomplicated urinary tract infections 2
Published on November 30, 2023
18 min
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:04
Now, in the recurrent UTI,
what should we do to reduce
recurrences in patients
with recurrent UTI?
Here you see again
the definition and
10% to 20% will have
recurrent UTIs.
This is very bad
for the patients.
The treatment of the acute
episode is not enough.
We need something
for prophylaxis.
0:30
First, we have to ask
about risk factors.
There are urogenital
risk factors:
incontinence, obstruction,
sphincter detrusor dyssynergia,
surgery. Of course,
these we have
either to improve
or to consider.
There are general risk factors
like the history of the
UTI. What does it mean?
The mother has history,
the daughter has recurrent UTIs.
This is genetic. And diabetes
mellitus, that is an
immune situation,
and oestrogen deficiency
in post-menopausal women.
But there are also behavioral
risk factors:
sexual intercourse,
diaphragm use, spermicides
and antibiotic usage,
as I have shown you.
1:12
Therefore, the
prevention should first
go to the risk factors. For
behavioral risk factors,
for example, patients
who don't take
enough fluid or delay urination
or post-coital urination delay,
or wiping from back to
front after defaecation.
We have to ask whether this
is very important or not.
There are not many
studies showing this.
In older women we have
urinary incontinence
and we have the so-called
non-secretor status.
This is of course genetic
or, if the patient
has cystocele or
post-void residual urine.
Then, I mentioned already,
sexual intercourse
frequency and using
different spermicides or
genetic factors affecting
the immune system.
Hide